102 related articles for article (PubMed ID: 36206301)
1. PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas.
Alrohaibani A; Yu Y; Gao L; McLean KM; Hetts J; Saglam O
Int J Gynecol Pathol; 2024 May; 43(3):284-289. PubMed ID: 38085958
[TBL] [Abstract][Full Text] [Related]
2. Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes.
McFarlane I; Porter JM; Brownsell E; Ghaoui N; Connolly KC; Herrington CS; Hollis RL
Front Oncol; 2024; 14():1399979. PubMed ID: 38854725
[TBL] [Abstract][Full Text] [Related]
3. Frontiers of Ovarian Carcinosarcoma.
Ismail A; Choi S; Boussios S
Curr Treat Options Oncol; 2023 Dec; 24(12):1667-1682. PubMed ID: 37938504
[TBL] [Abstract][Full Text] [Related]
4. Unveiling the mille-feuille sign: a key to diagnosing ovarian carcinosarcoma in addition to ovarian metastasis from colorectal carcinoma on MRI.
Watanabe Y; Matsuki M; Nakamata A; Masuoka S; Kikuchi T; Fujii H; Hamamoto K; Mori H; Fukushima N; Sakaguchi M; Todo S; Fujiwara H
Abdom Radiol (NY); 2024 Jun; ():. PubMed ID: 38860998
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
Zhang JQ; Zhao BB; Wang MM; Li L
Front Oncol; 2021; 11():603591. PubMed ID: 34938651
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression.
Bagheri M; Aisha Mohamed G; Mohamed Saleem MA; Ognjenovic NB; Lu H; Kolling FW; Wilkins OM; Das S; La Croix IS; Nagaraj SH; Muller KE; Gerber SA; Miller TW; Pattabiraman DR
bioRxiv; 2023 Apr; ():. PubMed ID: 37131809
[TBL] [Abstract][Full Text] [Related]
7. Benzophenone-3 alters expression of genes encoding vascularization and epithelial-mesenchymal transition functions during Trp53-null mammary tumorigenesis.
Morozova E; Kariagina A; Busch C; Schwartz RC
Food Chem Toxicol; 2024 Apr; 186():114540. PubMed ID: 38387520
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcoma of Breast Mimicking Breast Abscess.
Muslim S; Prasad G; Alam I; Singh SK; Nasrin N
Indian J Surg Oncol; 2018 Sep; 9(3):398-401. PubMed ID: 30288006
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report.
St Laurent JD; Abel MK; Liu J; Quade BJ; Davis MR
Gynecol Oncol Rep; 2024 Feb; 51():101322. PubMed ID: 38273934
[TBL] [Abstract][Full Text] [Related]
10. Carcinosarcoma of the Breast With An Unusual Secretory Carcinoma as the Carcinomatous Component.
Srinivas V; Harjai MM; Subramanya H; Rajaram T; Rai R
Med J Armed Forces India; 2004 Oct; 60(4):410-2. PubMed ID: 27407689
[No Abstract] [Full Text] [Related]
11. Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations.
Davidson B; Holth A; Lindemann K; Zahl Eriksson AG; Nilsen TA; Torgunrud A
Virchows Arch; 2024 May; ():. PubMed ID: 38733380
[TBL] [Abstract][Full Text] [Related]
12. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho GY; Vandenberg CJ; Lim R; Christie EL; Garsed DW; Lieschke E; Nesic K; Kondrashova O; Ratnayake G; Radke M; Penington JS; Carmagnac A; Heong V; Kyran EL; Zhang F; Traficante N; ; Huang R; Dobrovic A; Swisher EM; McNally O; Kee D; Wakefield MJ; Papenfuss AT; Bowtell DDL; Barker HE; Scott CL
Ther Adv Med Oncol; 2023; 15():17588359231208674. PubMed ID: 38028140
[TBL] [Abstract][Full Text] [Related]
13. Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Marks ZRC; Campbell NK; Mangan NE; Vandenberg CJ; Gearing LJ; Matthews AY; Gould JA; Tate MD; Wray-McCann G; Ying L; Rosli S; Brockwell N; Parker BS; Lim SS; Bilandzic M; Christie EL; Stephens AN; de Geus E; Wakefield MJ; Ho GY; McNally O; ; McNeish IA; Bowtell DDL; de Weerd NA; Scott CL; Bourke NM; Hertzog PJ
Nature; 2023 Aug; 620(7976):1063-1070. PubMed ID: 37587335
[TBL] [Abstract][Full Text] [Related]
14. IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NF‑κB signaling pathway.
Wang M; Wu Y; Li X; Dai M; Li S
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37539706
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY; Kyran EL; Bedo J; Wakefield MJ; Ennis DP; Mirza HB; Vandenberg CJ; Lieschke E; Farrell A; Hadla A; Lim R; Dall G; Vince JE; Chua NK; Kondrashova O; Upstill-Goddard R; Bailey UM; Dowson S; Roxburgh P; Glasspool RM; Bryson G; Biankin AV; ; Cooke SL; Ratnayake G; McNally O; Traficante N; ; DeFazio A; Weroha SJ; Bowtell DD; McNeish IA; Papenfuss AT; Scott CL; Barker HE
Cancer Res; 2022 Dec; 82(23):4457-4473. PubMed ID: 36206301
[TBL] [Abstract][Full Text] [Related]
16. Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract][Full Text] [Related]
17. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
